Sablich Kim
- SEC CIK
- 0001758790
No open-market purchases or sales filed in the past year.
Current role at each company
- JAZZ Jazz Pharmaceuticals plcEVP, GM of U.S.as of Jun 7, 2023
- EIGR Eiger BioPharmaceuticals, Inc.Directoras of Mar 3, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Sablich Kim as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
JAZZ Jazz Pharmaceuticals plc
EVP, GM of U.S.3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2023 (view filing) | Mar 8 | 2 days | Sablich KimEVP, GM of U.S., Commercial Ma | SSale | −3.01K | $139.74 | −$421.0K | −9.0%30.6K after | 2 lots |
| Jun 8, 2022 (view filing) | Jun 6-7 | 2 days | Sablich KimEVP & GM, North America | SSale | −3.83K | $151.45 | −$579.9K | −13.4%24.8K after | 6 lots |
| Nov 15, 2021 (view filing) | Nov 11 | 4 days | Sablich KimEVP & GM, North America | SSale | −2.75K | $135.01 | −$371.0K | −11.5%21.1K after |